Orchestra BioMed Holdings (OBIO) Price & Analysis

Compare

72 Followers

OBIO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.37 - $7.04

Previous CloseN/A

Volume15.92K

Average Volume (3M)348.19K

Market Cap

$128.31M

Enterprise Value$101.81M

Total Cash (Recent Filing)$49.88M

Total Debt (Recent Filing)$16.44M

Price to Earnings (P/E)―

Beta2.11

Next Earnings

Nov 18, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding48,057,190

10 Day Avg. Volume432,351

30 Day Avg. Volume348,193

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.79

Enterprise Value/Revenue35.28

Enterprise Value/Gross Profit38.10

Enterprise Value/Ebitda-1.48

Forecast

1Y Price Target

$12.00

Price Target Upside349.44% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Financial SupportLigand Pharmaceuticals will provide Orchestra BioMed with $20M in funding and purchase $5M of OBIO shares, with an additional $15M possible if milestones are met.

Regulatory MilestonesThe FDA has granted Breakthrough Device designation for atrioventricular interval modulation (AVIM) therapy.

Strategic PartnershipsOrchestra BioMed announced new strategic partnerships with Ligand Pharmaceuticals and Medtronic, indicating potential growth opportunities.

Bears Say

Financial ChallengesThe company may need to raise additional capital within the next 12 months, indicating a potential financial challenge.

Financial PerformanceNet loss was $18.8M, or ($0.49) per share, moderately higher than our estimated loss of $15.5M.

Risks And UncertaintiesRisks include failure of product candidates in clinical trials, failure to secure regulatory approval, and potential dilution risk, which could impact the company's future valuation.

Orchestra BioMed Holdings News

Orchestra BioMed secures over $111M in proceeds, committed capital

Orchestra BioMed (OBIO) announced the completion of strategic transactions and concurrent public and private equity offerings totaling an...

3d ago

MDT

LGND

Orchestra BioMed prices 9.4M shares at $2.75 in underwritten public offering

Orchestra BioMed (OBIO) announced the pricing of an underwritten public offering of 9,413,637 shares of its common stock...

7d ago

OBIO

Orchestra BioMed announces common stock offering, no amount given

Orchestra BioMed (OBIO) Holdings announced that it has commenced an underwritten public offering of shares of its common...

8d ago

OBIO

Nine new option listings on July 30th

New option listings for July 30th include Roundhill AMD WeeklyPay ETF (AMDW), Roundhill AVGO WeeklyPay ETF (AVGW), T-REX...

9d ago

DOMH

OBIO

Orchestra BioMed Holdings Closes $40M Public Offering

Orchestra BioMed Holdings ( ($OBIO) ) has provided an update. On August 1, 2025, Orchestra BioMed Holdings announced...

4d ago

OBIO

Strategic Partnerships and Financial Maneuvers Position Orchestra BioMed for Growth: A Buy Rating Justification

In a report released yesterday, Marie Thibault from BTIG maintained a Buy rating on Orchestra BioMed Holdings, with...

7d ago

OBIO

Orchestra BioMed Secures $70M for Cardiology Programs

Orchestra BioMed Holdings ( ($OBIO) ) has issued an update. On July 31, 2025, Orchestra BioMed Holdings announced...

8d ago

OBIO

Orchestra BioMed Confirms Director Elections and Auditor

Orchestra BioMed Holdings ( ($OBIO) ) has issued an update. On June 24, 2025, Orchestra BioMed Holdings, Inc....

1M ago

OBIO

Orchestra Biomed Reports Increased Losses Amid Revenue Growth

Orchestra Biomed Holdings, Inc. ( ($OBIO) ) has released its Q1 earnings. Here is a breakdown of the...

2M ago

OBIO

Promising Innovations and Strategic Advancements Drive Buy Rating for Orchestra BioMed Holdings

Orchestra BioMed Holdings (OBIO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst...

3M ago

OBIO

Orchestra BioMed reports Q1 EPS (49c), consensus (48c)

Reports Q1 revenue $868k, consensus $522.33k. David Hochman, Chairman and CEO of Orchestra BioMed (OBIO), stated: “We continued...

3M ago

OBIO

Orchestra BioMed announces continued expansion of global property estate

Orchestra BioMed (OBIO) announced continued expansion of its global intellectual property estate supporting its proprietary AVIM therapy pipeline....

3M ago

OBIO

Orchestra BioMed price target lowered to $12 from $16 at Barclays

Barclays lowered the firm’s price target on Orchestra BioMed (OBIO) to $12 from $16 and keeps an Overweight...

3M ago

OBIO

Orchestra BioMed Receives FDA Approval for IDE Amendment

Orchestra BioMed Holdings ( ($OBIO) ) just unveiled an update. On April 22, 2025, Orchestra BioMed Holdings announced...

3M ago

OBIO

OBIO FAQ

What was Orchestra Biomed Holdings, Inc.’s price range in the past 12 months?

Orchestra Biomed Holdings, Inc. lowest stock price was $2.37 and its highest was $7.04 in the past 12 months.

What is Orchestra Biomed Holdings, Inc.’s market cap?

Orchestra Biomed Holdings, Inc.’s market cap is $128.31M.

When is Orchestra Biomed Holdings, Inc.’s upcoming earnings report date?

Orchestra Biomed Holdings, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 102 days.

How were Orchestra Biomed Holdings, Inc.’s earnings last quarter?

Currently, no data Available

Is Orchestra Biomed Holdings, Inc. overvalued?

According to Wall Street analysts Orchestra Biomed Holdings, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Orchestra Biomed Holdings, Inc. pay dividends?

Orchestra Biomed Holdings, Inc. does not currently pay dividends.

What is Orchestra Biomed Holdings, Inc.’s EPS estimate?

Orchestra Biomed Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Orchestra Biomed Holdings, Inc. have?

Orchestra Biomed Holdings, Inc. has 48,057,190 shares outstanding.

What happened to Orchestra Biomed Holdings, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Orchestra Biomed Holdings, Inc.?

Currently, no hedge funds are holding shares in OBIO

Orchestra BioMed Holdings Stock Smart Score

Neutral

Fundamentals

Return on Equity

-179.12%

Trailing 12-Months

Asset Growth

-28.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Orchestra Biomed Holdings, Inc.

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Orchestra BioMed Holdings (OBIO) Earnings & Revenues

Historic Earnings Reports

OBIO Stock 12 Month Forecast

Average Price Target

$12.00

▲(349.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","4":"$4","7":"$7","10":"$10","13":"$13"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4,7,10,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.44,3.1753846153846155,3.9107692307692306,4.646153846153846,5.381538461538462,6.116923076923078,6.852307692307692,7.587692307692308,8.323076923076924,9.058461538461538,9.793846153846154,10.52923076923077,11.264615384615384,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.44,3.1753846153846155,3.9107692307692306,4.646153846153846,5.381538461538462,6.116923076923078,6.852307692307692,7.587692307692308,8.323076923076924,9.058461538461538,9.793846153846154,10.52923076923077,11.264615384615384,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.44,3.1753846153846155,3.9107692307692306,4.646153846153846,5.381538461538462,6.116923076923078,6.852307692307692,7.587692307692308,8.323076923076924,9.058461538461538,9.793846153846154,10.52923076923077,11.264615384615384,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.93,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.12,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.82,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.24,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.16,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.77,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >